Calreticulin mutations in myeloproliferative neoplasms

Area of Science:

• Molecular Biology
• Hematology
• Oncology

Background:

• Calreticulin (CALR) is an endoplasmic reticulum chaperone involved in protein glycosylation and calcium storage.
• CALR mutations were discovered in 2013, identified in approximately half of myeloproliferative neoplasm (MPN) patients lacking JAK2 or MPL mutations.
• These mutations significantly impact the understanding and treatment of MPNs.

Purpose of the Study:

• To review the clinical significance of CALR mutations in MPNs.
• To elucidate the molecular mechanisms by which CALR mutations drive MPN development.
• To highlight the diagnostic and therapeutic implications of CALR mutations.

Main Methods:

• Literature review of 8 years of research on CALR mutations in MPNs.
• Analysis of the interaction between mutant CALR and the thrombopoietin receptor (MPL).
• Investigation of CALR mutation expression on the cell surface.

Main Results:

• CALR mutations are present in a significant subset of MPN patients.
• CALR mutations interact with MPL, driving cellular transformation.
• Mutant CALR is expressed on the cell surface, presenting potential therapeutic targets.

Conclusions:

• CALR mutation status and type are crucial for MPN diagnosis and treatment decisions.
• The CALR-MPL interaction is a primary mechanism of transformation in CALR-mutated MPNs.
• CALR mutations offer promising targets for novel molecular-targeted drugs and immunotherapies for MPNs.